A Randomized, Blinded, Two-part, Phase II Trial to Evaluate the Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults 18 Years and Older
Latest Information Update: 04 Mar 2024
At a glance
- Drugs Recombinant two component COVID 19 vaccine Jiangsu Rec Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man; Pharmacodynamics; Therapeutic Use
- Acronyms ReCOV
- Sponsors Jiangsu Rec-Biotechnology
- 16 Dec 2023 Results from this and other study assessing Safety and Immunogenicity, published in the Infectious Diseases and Therapy
- 24 Apr 2023 Status changed from active, no longer recruiting to completed.
- 04 Oct 2022 According to clinicalytials.gov record, Protocol of this study has been amended, there is change in phase II/III to Phase II, Patient number has been decreased to 947 from 20301, Primary endpoint was changed as well, Interventional Study Model, Arms, Inclusion and Exclusion criteria of the trial were changed.